US Patent Issued to Five Prime Therapeutics on June 3 for "Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer" (California Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,738, issued on June 3, was assigned to Five Prime Therapeutics Inc. (South San Francisco, Calif.).

"Anti-FGFR2 antibodies in combination with chemotherapy agents in gastric cancer" was invented by Helen L. Collins (Atherton, Calif.), James Hnatyszyn (Foster City, Calif.), Hong Xiang (Palo Alto, Calif.) and Xiang Zhang (Burlingame, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy."

The patent ...